Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPL: Cemiplimab and Fianlimab with Radiotherapy in Locally Advanced NSCLC
NCT06865339Phase 2Recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab, cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Montefiore Medical Center. Started Aug 2025; status: recruiting.
02
Drugs
fianlimabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06865339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865339.